menu
    • menu
    [{"orgOrder":0,"company":"SCHULKE & MAYR G.M.B.H.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Octenidine Hydrochloride","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase III","graph3":"SCHULKE & MAYR G.M.B.H.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SCHULKE & MAYR G.M.B.H. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SCHULKE & MAYR G.M.B.H. \/ Undisclosed"},{"orgOrder":0,"company":"SCHULKE & MAYR G.M.B.H.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Octenidine Hydrochloride","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase III","graph3":"SCHULKE & MAYR G.M.B.H.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SCHULKE & MAYR G.M.B.H. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SCHULKE & MAYR G.M.B.H. \/ Undisclosed"},{"orgOrder":0,"company":"SCHULKE & MAYR G.M.B.H.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Octenidine Hydrochloride","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"SCHULKE & MAYR G.M.B.H.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SCHULKE & MAYR G.M.B.H. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SCHULKE & MAYR G.M.B.H. \/ Undisclosed"},{"orgOrder":0,"company":"Becton Dickinson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Octenidine Hydrochloride","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Becton Dickinson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Becton Dickinson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Becton Dickinson \/ Undisclosed"},{"orgOrder":0,"company":"Becton Dickinson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Octenidine Hydrochloride","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Becton Dickinson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Becton Dickinson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Becton Dickinson \/ Undisclosed"},{"orgOrder":0,"company":"SCHULKE & MAYR G.M.B.H.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Octenidine Hydrochloride","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"SCHULKE & MAYR G.M.B.H.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"SCHULKE & MAYR G.M.B.H. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"SCHULKE & MAYR G.M.B.H. \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Octenidine Hydrochloride

    Menu

    Octenidine Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SCHULKE & MAYR G.M.B.H.

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            SCHULKE & MAYR G.M.B.H.

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Octenidine Hydrochloride

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Assess the Inhibition of Plaque Formation in Subjects With a Gingival Index ≤1.5

                            Details : Octenidine Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dental Plaque.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 19, 2017

                            Lead Product(s) : Octenidine Hydrochloride

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SCHULKE & MAYR G.M.B.H.

                            Germany arrow
                            ACI Convention
                            Not Confirmed

                            SCHULKE & MAYR G.M.B.H.

                            Germany arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Octenidine Hydrochloride

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Assess the Inhibition of Plaque Formation in Subjects With a Gingival Index ≤1.5

                            Details : Octenidine Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dental Plaque.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 26, 2017

                            Lead Product(s) : Octenidine Hydrochloride

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Becton Dickinson

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Becton Dickinson

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Octenidine Hydrochloride

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Antimicrobial Effectiveness of an Antimicrobial Cloth

                            Details : Octenidine Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 26, 2017

                            Lead Product(s) : Octenidine Hydrochloride

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Becton Dickinson

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Becton Dickinson

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Octenidine Hydrochloride

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effectiveness of an Antimicrobial Agent for Preoperative Skin Preparation

                            Details : Octenidine Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 21, 2017

                            Lead Product(s) : Octenidine Hydrochloride

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            SCHULKE & MAYR G.M.B.H.

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            SCHULKE & MAYR G.M.B.H.

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Octenidine Hydrochloride

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose Finding Study to Assess Octenidine Mouthwash Concentrations in Comparison to Placebo

                            Details : Octenidine Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Gingivitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 14, 2014

                            Lead Product(s) : Octenidine Hydrochloride

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            SCHULKE & MAYR G.M.B.H.

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            SCHULKE & MAYR G.M.B.H.

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Octenidine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Efficacy of Octenisept® in Patients With Chronic Wounds

                            Details : Octenisept is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Leg Ulcer.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 15, 2011

                            Lead Product(s) : Octenidine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth